دورية أكاديمية
أعرض في EDS

Recipient ABCB1, donor and recipient CYP3A5 genotypes influence tacrolimus pharmacokinetics in liver transplant cases.

التفاصيل البيبلوغرافية
العنوان: Recipient ABCB1, donor and recipient CYP3A5 genotypes influence tacrolimus pharmacokinetics in liver transplant cases.
المؤلفون: Naushad SM; Department of Pharmacogenomics, Sandor Lifesciences Pvt Ltd, Hyderabad, India. Electronic address: naushadsm@gmail.com., Pavani A; Department of Pharmacogenomics, Sandor Lifesciences Pvt Ltd, Hyderabad, India., Rupasree Y; Department of Pharmacogenomics, Sandor Lifesciences Pvt Ltd, Hyderabad, India., Hussain T; Center of Excellence in Biotechnology Research, College of Science, King Saud University, Riyadh, Saudi Arabia., Alrokayan SA; Department of Biochemistry, College of Science, King Saud University, Riyadh, Saudi Arabia., Kutala VK; Department of Clinical Pharmacology and Therapeutics, Nizam's Institute of Medical Sciences, Hyderabad, India.
المصدر: Pharmacological reports : PR [Pharmacol Rep] 2019 Jun; Vol. 71 (3), pp. 385-392. Date of Electronic Publication: 2019 Jan 11.
نوع المنشور: Journal Article; Meta-Analysis
اللغة: English
بيانات الدورية: Publisher: Springer International Publishing Country of Publication: Switzerland NLM ID: 101234999 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2299-5684 (Electronic) Linking ISSN: 17341140 NLM ISO Abbreviation: Pharmacol Rep Subsets: MEDLINE
أسماء مطبوعة: Publication: 2020- : Cham, Switzerland : Springer International Publishing
Original Publication: Kraków, Poland : Institute of Pharmacology, Polish Academy of Sciences, c2005-
مواضيع طبية MeSH: Cytochrome P-450 CYP3A/*genetics , Tacrolimus/*pharmacokinetics, ATP Binding Cassette Transporter, Subfamily B/genetics ; Genotype ; Graft Rejection/metabolism ; Humans ; Immunosuppression Therapy/methods ; Liver Transplantation/methods ; Polymorphism, Genetic/genetics ; Tissue Donors
مستخلص: Background: Effective immunosuppression through optimization of trough levels tacrolimus reduces post-transplant mortality rate in liver transplant cases.
Methods: Meta-analysis was carried out to evaluate how donor/recipient CYP3A5 (n = 678) and recipient ABCB1 (n = 318) genotypes influence tacrolimus pharmacokinetics till one-month of transplantation.
Results: The donor CYP3A5*3/*3 genotype exhibited higher concentration/dose (C/D) ratio of tacrolimus in week 1 (mean difference: 65.04, 95% CI: 15.30-114.79 ng/ml/mg/kg), week 2 (mean difference: 21.7, 95% CI: 12.6-30.9 ng/ml/mg/kg) and week 4 (mean difference: 43.28, 95% CI: 17.09 - 69.49 ng/ml/mg/kg) compared to *1/*1 and *1/*3 genotypes. The recipient CYP3A5 *3/*3 genotype did not showed significant difference in tacrolimus C/D ratio in week 1 compared to other two genotypes. However, week 2 (mean difference: 44.16, 95% CI: 3.68-84.65 ng/ml/mg/kg) and week 4 (mean difference: 43.74, 95% CI: 12.50-75.00 ng/ml/mg/kg) availability was higher in *3/*3 mutant recipients. However, the recipient ABCB1 3435 C > T polymorphism has no significant influence on tacrolimus pharmacokinetics till one month of transplant.
Conclusions: The donor and recipient CYP3A5*3 polymorphism influences tacrolimus pharmacokinetics in the first month post-transplantation, whereas the association with recipient ABCB1 3435 C > T is inconclusive.
(Copyright © 2019 Institute of Pharmacology, Polish Academy of Sciences. Published by Elsevier B.V. All rights reserved.)
فهرسة مساهمة: Keywords: ABCB1; CYP3A5; Liver transplantation; Pharmacokinetics; Tacrolimus
المشرفين على المادة: 0 (ABCB1 protein, human)
0 (ATP Binding Cassette Transporter, Subfamily B)
EC 1.14.14.1 (CYP3A5 protein, human)
EC 1.14.14.1 (Cytochrome P-450 CYP3A)
WM0HAQ4WNM (Tacrolimus)
تواريخ الأحداث: Date Created: 20190420 Date Completed: 20191120 Latest Revision: 20211204
رمز التحديث: 20240628
DOI: 10.1016/j.pharep.2019.01.006
PMID: 31003147
قاعدة البيانات: MEDLINE
الوصف
تدمد:2299-5684
DOI:10.1016/j.pharep.2019.01.006